Cellular Biomedicine, a biopharma headquartered in Maryland with operations in Shanghai, signed a definite $383 million go-private merger agreement with a company formed by management and an investment syndicate. CBMG is developing immunotherapies for cancer and stem cell therapies for degenerative diseases. The agreement was set at $19.75 per share, slightly higher than the original $19.50 per share offered last fall and 31% above the company's average price over the last 30 days. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //